Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ART-123 to prevent oxaliplatin-induced peripheral sensory neuropathy
jRCT2051250045Phase 3Recruiting
- Sponsor
- Asahi Kasei Corporation
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in peripheral neuropathy (CIPN) comparing ART-123 arm with Placebo arm (2 arms). Primary endpoint: Change from baseline in total FACT/GOG-NTX4 score. Started Jun 2025; status: recruiting.
02
Drugs
thrombomodulin alfa
03
Conditions
peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on jRCT2051250045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250045.